升主动脉疾病的血管内支架移植治疗:系统综述与荟萃分析
该研究按PRISMA指南系统检索并汇总升主动脉局限病变(不累及弓部血管)行TEVAR的患者资料,约67%有既往心脏手术史,主要适应证为Stanford A型夹层(49%)与假性动脉瘤(28%)。技术成功率95.5%,早期死亡2.9%,晚期内漏16.4%,提示对选定患者安全可行,但仍需更大样本研究。
要点
- 升主动脉TEVAR技术成功率达95.5%,早期死亡仅2.9%。
- 晚期内漏16.4%、再手术8.9%,需重视远期随访。
- 多用于有既往心脏手术史、不适合开放手术的选定患者。
核心结论
- 升主动脉TEVAR对多种升主动脉疾病的选定患者似乎安全可行,但仍需更大规模研究验证。
研究设计与样本
- 按PRISMA指南开展的系统综述与荟萃分析,分别汇总病例报告与病例系列,计算结局率的合并比例及95%CI。
- 研究对象为病变局限于升主动脉且不累及弓部血管、接受TEVAR的患者。
主要发现
- 约67%的患者有既往心脏手术史。
- TEVAR主要用于急性或慢性Stanford A型夹层(49%)或假性动脉瘤(28%)。
- 器械多经股动脉入路(67%),近半数患者使用快速心室起搏。
- 技术成功率为95.5%(95%CI,87.8-99.8)。
- 早期转为开放手术为0.7%(95%CI,0.1-4.8),死亡率为2.9%(95%CI,0.02-8.6)。
临床怎么用
- 对不适合传统开放手术、病变局限于升主动脉的选定患者,TEVAR可作为可行选择。
- 应关注晚期内漏与再手术风险,术后需规范影像随访。
局限性
- 纳入研究以病例报告与病例系列为主,证据等级有限。
- 作者指出仍需更大规模研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Conventional open surgery encompassing cardiopulmonary bypass has been traditionally used for the treatment of ascending aorta diseases. However, more than one in five of these patients will be finally considered unfit for open repair. We conducted a systematic review and meta-analysis to investigate the role of thoracic endovascular aortic repair (TEVAR) for aortic diseases limited to the ascending aorta. METHODS: The current meta-analysis was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We investigated patients' baseline characteristics along with early (30 days/in-hospital stay) and late (beyond 30 days/in-hospital stay) outcomes after TEVAR limited to the ascending aorta and not involving the arch vessels. Separate analyses for case reports and case series were conducted, and pooled proportions with 95% confidence intervals (CIs) of outcome rates were calculated. RESULTS: Approximately 67% of the patients had a prior cardiac operation. TEVAR was performed mainly for acute or chronic Stanford type A dissection (49%) or pseudoaneurysm (28%). The device was usually delivered through the femoral artery (67%), and rapid ventricular pacing was used in nearly half of the patients. Technical success of the method was 95.5% (95% CI, 87.8-99.8). Among the early outcomes, conversion to open repair was 0.7% (95% CI, 0.1-4.8), whereas mortality was 2.9% (95% CI, 0.02-8.6). We estimated a pooled rate of 1.8% (95% CI, 0.1-7.0) for neurologic events (stroke or transient ischemic attack) and 0.8% (95% CI, 0.1-5.6) for myocardial infarction. Late endoleak was recorded in 16.4% (95% CI, 8.2-26.0), and 4.4% (95% CI, 0.1-12.4) of the population died in the postoperative period. Finally, reoperation was recorded in 8.9% (95% CI, 3.1-16.4) of the study sample. CONCLUSIONS: TEVAR in the ascending aorta seems to be safe and feasible for selected patients with various aortic diseases, although larger studies are required.
引用
- Baikoussis NG, Antonopoulos CN, Papakonstantinou NA, et al. Endovascular stent grafting for ascending aorta diseases. J Vasc Surg. 2017. PMID: 28830707. doi:10.1016/j.jvs.2017.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。